In ovarian cancer patients, the combination therapy of varlilumab and nivolumab resulted in increased tumor expression of PD-L1 and CD8+ tumor infiltrating lymphocytes in 61% and 58% of patients, respectively (61). The gene discussed is CD274; the disease is neoplasm.